tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Alveolar Bone Loss D016301 10 associated lipids
Glycosuria D006029 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Fatigue D005221 10 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Long QT Syndrome D008133 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Vision Disorders D014786 10 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dyspnea D004417 10 associated lipids
Hemophilia A D006467 10 associated lipids
Shock D012769 11 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Thinness D013851 11 associated lipids
Shock, Septic D012772 11 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Dehydration D003681 11 associated lipids
Influenza, Human D007251 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Hyperpigmentation D017495 11 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Retinoblastoma D012175 12 associated lipids
Listeriosis D008088 12 associated lipids
Osteoporosis D010024 12 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Eye Diseases D005128 12 associated lipids
Crohn Disease D003424 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Keloid D007627 12 associated lipids
Hypertension, Portal D006975 12 associated lipids
Biliary Fistula D001658 13 associated lipids
Urticaria D014581 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Corneal Diseases D003316 13 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Critical Illness D016638 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Stomatitis D013280 14 associated lipids
Vasculitis D014657 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Alopecia D000505 14 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Ischemia D007511 18 associated lipids
Albuminuria D000419 18 associated lipids
Down Syndrome D004314 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Watanabe K et al. Prolongation effect of a small dose of FK506, cyclosporine, or azathioprine on renal allografts in dogs treated with fractionated lymphoid irradiation and donor bone marrow cell infusion. 1989 Transplant. Proc. pmid:2468213
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Ochiai T et al. Comparative studies on the immunosuppressive activity of FK506, 15-deoxyspergualin, and cyclosporine. 1989 Transplant. Proc. pmid:2468228
Yasunami Y et al. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat. 1989 Transplant. Proc. pmid:2468234
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Arai K et al. Prolonged limb allograft survival with short-term treatment with FK-506 in rats. 1989 Transplant. Proc. pmid:2468256
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Hatanaka H et al. FK-506 related compounds produced by Streptomyces tsukubaensis No. 9993. 1989 J. Antibiot. pmid:2470720
Gschwendt M et al. The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. 1989 Immunobiology pmid:2471685
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Moriyama S [Experimental tracheal reconstruction by allotransplantation]. 1989 Nihon Kyobu Geka Gakkai Zasshi pmid:2475555
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Francavilla A et al. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. 1989 Lancet pmid:2479802
Walliser P et al. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. 1989 Immunology pmid:2480331
Aoki M et al. [Histological observations of immunosuppressive effects of FK-506 in canine lung allotransplantation]. 1989 Bull Chest Dis Res Inst Kyoto Univ pmid:2482787
Kay JE and Benzie CR T lymphocyte activation through the C28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506. 1989 Immunol. Lett. pmid:2483716
Leonard DK et al. Toxicity of FK-506 in human fetal pancreas. 1989 Diabetes pmid:2463195
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701
Inamura N et al. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. 1988 Clin. Immunol. Immunopathol. pmid:2446810
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Tsuchimoto S et al. [Orthotopic liver transplantation in the rat--immunosuppressive effect of FR100906 on the survival of liver allografts]. 1988 Nihon Geka Gakkai Zasshi pmid:2452341
Nakajima K et al. Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. 1988 Transplantation pmid:2454521
Todo S et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. 1988 Surgery pmid:2456627
Kawashima H et al. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. 1988 Invest. Ophthalmol. Vis. Sci. pmid:2458329
Warty V et al. FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. 1988 Transplantation pmid:2458643
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
Woo J et al. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. 1988 Immunology pmid:2460401
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. 1988 J. Antibiot. pmid:2461926
Inamura N et al. Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats. 1988 Int. J. Immunopharmacol. pmid:2463974
Hatanaka H et al. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. 1988 J. Antibiot. pmid:3198493